148
26. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN,
1973. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
(Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA. 70: 1174--
1178.
27. Goswami BB, Borek E, Shalma DK, Fujitaki J, Smith RA, 1979. The broad spectrum
antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophis. Res. Commun. 89:
830--836.
28. Eriksson B, Helgstrand E, Johannson N, Larsson A, Misionny, A, Noren JO, Philipson
L, Stenberg K, Stening G, Stridh S, Oberg B, 1977. Inhibition of influenza virus
ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11:
946--951.
29. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu
MF, Rotstein O, Phillips MJ, Levy G, 1998. Ribavirin inhibits viral-induced macrophage
production of TNF, IL-1, the procoagulant fgl2 prothrombinase, and preserves TH1
cytokine production but inhibits TH2 cytokine response. J. Immunol. 160: 3487--3493.
30. Scheidel LM, Durbin RK, Stollar V, 1987. Sindbis Virus mutants resistant to
Mycophenolic Acid and Ribavirin. Virology 158: 1--7.
31. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N, 1985. Simplified
plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21
cells: comparison of the BHK suspension test with standard plaque reduction
neutralization. J Clin Microbiol; 22: 250--254.
32. Diamond MS, Zachariah M, Harris E, 2002. Mycophenolic Acid inhibits Dengue virus
infection by preventing replication of viral RNA. Virology 304: 211--221.
33. Lipsky JJ, 1996. Mycophenolate mofetil. Lancet 348: 1357--1359.
34. Scheidel LM, Stollar V, 1991. Mutations that confer resistance to mycophenolic acid
and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181: 490--
499.
35. Jin H, Elliot RM, 1993. Non-viral sequences at the 5’ends of Dugbe nairovirus S
mRNAs. J. Gen. Virol. 74: 2293--2297.
36. Tan ELC, Ooi EE, Lin C, Tan HC, Ling AE, Lim B, Stanton LW, 2004. Inhibition of
SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infec.
Dis. 10: 581--586.
37. Allen LB, 1980. Review of in vivo efficacy of ribavirin. Smith RA, Kirkpatrick W, eds,
Ribavirin: a broad spectrum antiviral agent. Academic Press, Inc., New York, 43--58.